International legal practice Osborne Clarke has advised Turbine, a company simulating cellular decision making to unlock novel oncology therapies, on raising EUR 5.7 million (USD 6.85m) as part of the successful closing of its pre-Series A round. The transatlantic round was co-led by new investors Accel and XTX Ventures and included Boston Millenia Partners who joined the existing syndicate comprising Delin Ventures, Atlantic Labs and o2h Ventures.
Most wet-lab experiments offer limited insight into the complex underlying biology of the disease. As a result, existing preclinical models in oncology often fail to translate into successful drugs in the clinic. To improve these outcomes, Turbine has created the Simulated Cell™ comprising an advanced digital model of human cell behaviour and cloud-based simulated experiments. The Simulated Cell™ can rapidly run unlimited number of experiments in comparison to wet-lab methods.
The platform – guided by AI algorithms – offers significant benefits over industry gold standard screening methods, such as CRISPR, by providing granular insight into the molecular mechanism of target-disease interactions. Supported by an enhanced biological understanding of the target intervention and the subset of cancer patients most likely to respond, Turbine’s simulation-based approach increases the likelihood of clinical success.
Osborne Clarke's corporate team is widely recognised as a leading European law firm for companies operating in the life science and healthcare sector team. Its sector team has a strong track record of providing highly sophisticated advice to investors and digital health clients on cutting-edge issues, across multiple service lines. They work with blue chip venture capital firms, the biggest pharma, medical devices, medtech and digital health companies in the market.